company background image
SPRY logo

ARS Pharmaceuticals NasdaqGM:SPRY Stock Report

Last Price

US$12.36

Market Cap

US$1.2b

7D

8.0%

1Y

35.4%

Updated

24 Mar, 2025

Data

Company Financials +

ARS Pharmaceuticals, Inc.

NasdaqGM:SPRY Stock Report

Market Cap: US$1.2b

SPRY Stock Overview

A biopharmaceutical company, develops treatments for severe allergic reactions. More details

SPRY fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance2/6
Financial Health3/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

ARS Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for ARS Pharmaceuticals
Historical stock prices
Current Share PriceUS$12.36
52 Week HighUS$18.51
52 Week LowUS$7.55
Beta1.41
1 Month Change9.96%
3 Month Change8.33%
1 Year Change35.38%
3 Year Changen/a
5 Year Changen/a
Change since IPO103.96%

Recent News & Updates

ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions

Feb 06

Recent updates

ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions

Feb 06

ARS Pharmaceuticals: Demand Curve Is Key Unknown

Nov 20

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

Sep 13
We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval

Sep 06

ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles

Jun 25

We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate

Mar 18
We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

Nov 14
ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

Shareholder Returns

SPRYUS BiotechsUS Market
7D8.0%-2.4%-0.2%
1Y35.4%-6.8%8.1%

Return vs Industry: SPRY exceeded the US Biotechs industry which returned -6.8% over the past year.

Return vs Market: SPRY exceeded the US Market which returned 7.9% over the past year.

Price Volatility

Is SPRY's price volatile compared to industry and market?
SPRY volatility
SPRY Average Weekly Movement10.6%
Biotechs Industry Average Movement10.5%
Market Average Movement6.4%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: SPRY has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: SPRY's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015158Rich Lowenthalars-pharma.com

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

ARS Pharmaceuticals, Inc. Fundamentals Summary

How do ARS Pharmaceuticals's earnings and revenue compare to its market cap?
SPRY fundamental statistics
Market capUS$1.21b
Earnings (TTM)US$8.00m
Revenue (TTM)US$89.15m

151.6x

P/E Ratio

13.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SPRY income statement (TTM)
RevenueUS$89.15m
Cost of RevenueUS$20.56m
Gross ProfitUS$68.59m
Other ExpensesUS$60.59m
EarningsUS$8.00m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.082
Gross Margin76.94%
Net Profit Margin8.97%
Debt/Equity Ratio27.0%

How did SPRY perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/24 03:13
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ARS Pharmaceuticals, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerCantor Fitzgerald & Co.
Roanna Clarissa RuizLeerink Partners LLC
Andreas ArgyridesOppenheimer & Co. Inc.